KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Current Assets: 2009-2024

Historic Current Assets for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to $3.3 billion.

  • Alnylam Pharmaceuticals' Current Assets rose 17.80% to $4.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 billion, marking a year-over-year increase of 17.80%. This contributed to the annual value of $3.3 billion for FY2024, which is 10.48% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Current Assets stood at $3.3 billion for FY2024, which was up 10.48% from $3.0 billion recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Current Assets ranged from a high of $3.3 billion in FY2024 and a low of $2.6 billion during FY2020.
  • Over the past 3 years, Alnylam Pharmaceuticals' median Current Assets value was $3.0 billion (recorded in 2023), while the average stood at $3.0 billion.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Current Assets surged by 52.39% in 2020 and then decreased by 4.14% in 2022.
  • Alnylam Pharmaceuticals' Current Assets (Yearly) stood at $2.6 billion in 2020, then grew by 7.41% to $2.8 billion in 2021, then fell by 4.14% to $2.7 billion in 2022, then increased by 10.79% to $3.0 billion in 2023, then climbed by 10.48% to $3.3 billion in 2024.